NEW YORK — Eurofins Scientific said today that it has acquired Transplant Genomics (TGI), a developer of molecular diagnostics for the management of organ transplant patients, for an undisclosed amount.
TGI offers a DNA microarray test called TruGraf that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function, providing an alternative to surveillance biopsies. The Mansfield, Massachusetts-based company is also developing additional tests for kidney and liver graft dysfunction, as well as companion diagnostics for immunosuppressants and immune status tests.
According to Eurofins, the acquisition will complement its existing transplant diagnostic portfolio, which includes Colorado-based pretransplant lab VRL and Missouri-based specialty post-transplant lab Viracor. Financial terms of the deal were not disclosed.
"This acquisition significantly reinforces the large existing range of innovative tests our group [of] laboratories offers to transplant hospitals and practitioners in the United States, and strengthens Eurofins leadership position in the transplant testing market and our ability to deploy the latest scientific advances to benefit patients," Gilles Martin, CEO of Luxembourg-based Eurofins, said in a statement.